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Abstract
Background: Genome-wide association studies show that most human traits and diseases are caused by a
combination of environmental and genetic causes, with each one of these having a relatively small effect. In
contrast, most therapies based on macromolecules like antibodies, antisense oligonucleotides or peptides focus on
a single gene product. On the other hand, complex organisms seem to have a plethora of functional molecules
able to bind specifically to multiple genes or genes products based on their sequences but the mechanisms that
lead organisms to recruit these multispecific regulators remain unclear.
Results: The mutational biases inferred from the genomic sequences of six organisms show an increase in the
variance of sequence interactivity in complex organisms. The high variance in the interactivity of sequences presents
an ideal evolutionary substrate to recruit sequence-specific regulators able to target multiple gene products. For
example, here it is shown how the 3’UTR can fluctuate between sequences likely to be complementary to other
sites in the genome in the search for advantageous interactions. A library of nucleotide- and peptide-based
tools was built using a script to search for candidates (e.g. peptides, antigens to raise antibodies or antisense
oligonucleotides) to target sequences shared by key pathways in human disorders, such as cancer and immune
diseases. This resource will be accessible to the community at www.wikisequences.org.
Conclusions: This study describes and encourages the adoption of the same multitarget strategy (e.g., miRNAs,
Hsp90) that has evolved in organisms to modify complex traits to treat diseases with robust pathological
phenotypes. The increase in the variance of sequence interactivity detected in the human and mouse genomes
when compared with less complex organisms could have expedited the evolution of regulators able to interact to
multiple gene products and modulate robust phenotypes. The identification of sequences common to more than
one therapeutic target carried out in this study could facilitate the design of new multispecific methods able to
modify simultaneously key pathways to treat complex diseases.
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Background
Genome-wide association studies have established that
most human traits and diseases are caused by a combin-
ation of environmental and genetic causes. The vast ma-
jority of these causes have relatively small effects on a
particular trait. For example, intelligence is highly herit-
able, but the variability of the trait corresponds to the
additive nature of multiple genotypes and their interac-
tions [1]. Potentially, very different allelic combinations
could produce equally gifted individuals. Equally, many
human diseases, such as cancer, or immune disorders,
should also fall into this polygenic category [2]. In con-
trast, many therapeutic approaches focus on modulating
the abundance of a single gene product or targeting a sin-
gle receptor. Developing a single compound to target the
gene that has the largest effect in most patients can be a
good strategy in some cases. Nevertheless, even when the
effect on the phenotype is sufficient, with time, the success
of treatment can be hampered by the upregulation of
pathways other than the one that is being targeted.
Redundant pathways are very common in complex or-
ganisms, and some have been maintained over millions of
years [3]. During evolution, higher organisms have re-
cruited multitarget regulatory elements that are capable of
modifying these robust networks and reconcile maintain-
ing functionality under mutational pressure with being
able to rapidly adapt the phenotype to the environment.
Of note among these regulatory elements are microRNAs
(miRNA) and heat shock protein 90 (Hsp90). miRNAs are
short RNA molecules (19–24 nucleotides long)[4, 5] that
generally downregulate gene expression by guiding the
RNA-induced silencing complex (RISC) to a number of
complementary mRNAs. In fact, miRNAs have been
shown to play a role in increasing the canalization and
tunability of networks [6–8]. In contrast, Hsp90 stabilizes
proteins after synthesis and exposure to heat. Hsp90 has
been described as an evolutionary capacitor that allows
genomes to store genetic diversity in complex traits with-
out exposing them to natural selection [9, 10].
Recently, the development of therapies that modulate
these multi-regulatory elements has been actively pursued,
e.g., therapies modulating miRNA levels in cancer [11, 12]
or in cardiovascular diseases [13, 14]. Additionally, the in-
hibition of Hsp90 activity has also shown potential in mul-
tiple studies, mainly in cancer research [15–17]. The main
caveat of modulating natural combinatory elements is that
they can potentially target many mRNAs or proteins that
are unrelated to the particular pathology of interest, caus-
ing off-target effects. Therefore, it would be ideal to design
tailored multi-regulatory tools.
The aim of this work was to study the strategy by which
organisms modify complex traits in order to inspire the
design of new therapeutic tools that are able to alter ro-
bust disease phenotypes. First, we analyzed on the features
of complex genomes that maintain high variances in the
interactivity of their sequences and mutational biases,
facilitating the search for advantageous interactions
with other sequences. Then, a library was built of mo-
lecular effectors to potentially target multiple key gene
products involved in human disorders that display com-
plex pathological networks.
Methods
DNA and amino acid datasets
DNA and protein sequences were accessed from the National
Center for Biotechnology Information (NCBI) database
(www.ncbi.nlm.nih.gov) and Ensemble (www.ensembl.org) for
the following species: Ec (Escherichia coli CFT073 assembly
eschColi_536), At (Arabidopsis thaliana assembly TAIR9),
Ce (Caenorhabditis elegans assembly WBcel235), Dm
(Drosophila melanogaster assembly BDGP5), Mm (Mus
musculus C57BL/6 J assembly GRCm38/mm10) and Hs
(Homo sapiens assembly GRCh37). Sequences were identi-
fied and subjected to BLAST searches using tools found
on the Ensemble (www.ensembl.org), UCSC Genome
Browser (www.genome.ucsc.edu) and Galaxy websites
(www.galaxyproject.org) [18]. BLAST searches in cDNA
were performed on a random collection of 48 sequences
with different percentages of low- or high-frequency dinu-
cleotides using the following parameters, search sensitiv-
ity: exact matches; E: 100; filter: none; w: 2; wink: 1. Ratios
of dinucleotide frequencies were calculated using total
genomic counts.
Sequences present in more than one gene product in-
volved in human diseases and not included in any other
mRNA or protein were searched from a collection of 308
gene and 1105 peptide sequences related to cancer, and 72
gene and 344 peptide sequences related to immune disor-
ders. These sequences were subjected to searches using
custom scripts written in visual basic. Rather than searching
for conserved protein domains and functional sites using
alignment algorithms, the search was performed by dividing
each cDNA or protein of interest into a matrix of multiple
cells of 12 nucleotides or 4 amino acids, respectively, and
then, a script was run to search for repeated cells. This
method increases the sensitivity of the search by removing
the negative influence of non-common flanking sequences.
Based on these sequences, a library was built containing nu-
cleotide- and peptide-based tools capable of simultaneously
targeting key cancer pathways or other diseases with a strong
genetic background. This resource is accessible to the com-
munity at www.wikisequences.org. This webpage will also be
open to users to upload their own sequences of interest and
for linking to their manuscripts. Protein topology was
assigned according to Uniprot annotation (www.uniprot.org)
and TMHMM (http://www.cbs.dtu.dk/services/TMHMM/),
whereas peptide structure was predicted using PEP-FOLD,
which is based on hidden Markov models [19, 20].
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Statistical analysis
Statistical analyses were conducted in R (http://www.
r-project.org/). Plots of the sequence frequency in the
cDNA relative to the length and percentage of high-
frequency dinucleotides (CA, AT, GC, AG) were con-
structed using local spline fitting (‘locfit’ function) to
generate a smoothed surface. Error bars represent 95 %
confidence intervals (binomial distributions) in compari-
son with random expectations.
Results
Sequences as targets of multispecific molecular effectors
Many interactions between genes involve sequence-
specific regulation of promoters, transcripts or proteins
[21, 22]. The nucleotide distribution in the sequences of
organisms of different complexity is important for un-
derstanding how the different layers of regulation are
recruited. In Fig. 1, we can observe changes in the di-
nucleotide frequencies observed in species of different
complexity: Ec (Escherichia coli CFT073), At (Arabidop-
sis thaliana), Ce (Caenorhabditis elegans), Dm (Drosoph-
ila melanogaster), Mm (Mus musculus) and Hs (Homo
sapiens). Some of these changes could reflect mutational
biases that were revealed after the release of the pressure
to bias codon composition to optimize translation profi-
ciency. Others could correspond to new mutational
biases. One such bias is the well-known high mutability
and scarcity of CpGs in vertebrates [23]. Interestingly,
also note the decrease in the TA/AT ratio from the low-
est values, found in E. coli, to those in eukaryotes (TA,
not AT, is present in two of three stop codons).
Although Fig. 1 provides a good summary of how the
nucleotide distribution varies with organism complexity,
it provides substantially less information about how
these asymmetries can affect the frequency distribution
of longer sequences. Consequently, plots for the fre-
quency of 10–16 nt sequences were constructed for each
species by blasting sequences with different proportions
of the most common dinucleotides against the cDNA of
each species (Fig. 2). We can observe that these di-
nucleotide asymmetries can add up to striking increases
in the frequency of longer sequences. Figure 2 also re-
veals how Mus musculus and Homo sapiens show an in-
creased slope in sequence frequency depending on the
nucleotide composition when compared with other or-
ganisms. Considering complementarity as the basis for
interaction with regulatory elements, we could also de-
scribe this observation as an increase in the variance of
sequence interactivity.
During the evolution of complexity, organisms have
allowed or recruited mutational biases that have shaped
the frequency of some of these sequences to the point of
having combinations of nucleotides or amino acids that are
rarely formed, whereas others act as attractors regardless
of any direct selective pressure. For example, the frequen-
cies of sequences in human cDNA comprising a random
collection of low-frequency or high-frequency dinucleo-
tides in human cDNA are shown in Fig. 1 (E and F, re-
spectively). In Fig. 3a, it is shown how these asymmetries
in the ratios of dinucleotide frequencies are especially evi-
dent in mouse and in human when compared with less
complex species. In human genes the strength of the
asymmetries increases gradually from 5’ to 3’ and is of
similar strength in the 3’UTR as in the rest of the genome
(Fig. 3b). Human sequences in the 3’UTR have a very
similar dinucleotide composition to the rest of the genome
in comparison with the 5’UTR, increasing the likelihood
of interactions with other sequences by complementarity.
The high variance in the interactivity of sequences could
facilitate the adoption of sequence-specific regulators able
to target multiple gene products. 3’UTR is also the main
target of miRNAs and, interestingly, the distribution of
the nucleotide sequences described in this study as having
therapeutic potential for multitargeting also show a sig-
nificant trend toward being more commonly located in
the 3’UTR, with decreasing frequency approaching the
5’UTR (Fig. 3c).
Building a library of nucleotide- and peptide-based multi-
specific macromolecules
Multispecific molecular effectors that target sequences com-
mon to more than one gene or receptor have the potential
to alter robust disease phenotypes. The identification of
short sequences common to multiple genes by alignment al-
gorithms can be hampered by the negative influence of non-
common flanking sequences. Using a script that increases
the sensitivity of the search by removing this influence, a li-
brary of nucleotide- and peptide-based tools was built to
contain more than one gene product involved in a particular
human disease that is not included in any other mRNA or
protein. An extract of this library is presented here in
Tables 1 and 2 (and in Supplementary Information
Additional file 1: Table S1 and Additional file 2: Table S2).
This library will also be available at the website www.wikise-
quences.org, which is open to the community for uploading
other sequences of interest and linking them to manuscripts.
These sequences could be targeted alone or in com-
bination, depending on the pathological pathways that
are involved. For therapeutic purposes, these sequences
could be manipulated using small-interfering RNAs (siR-
NAs), antisense oligonucleotides such as locked nucleic
acids (LNAs) [24, 25], tricyclo-DNA [26, 27], 2'-O-meth-
oxyethyls (MOEs) [28, 29], morpholinos [30], peptide
nucleic acids (PNAs) [31] or other silencing effectors
expressed in viral constructs or plasmids [32] (Table 1).
Incorporating conformationally restricted nucleotide
monomers into oligonucleotides through the use of
intercalators or extra bridges between atoms, as in the
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case of LNAs or tricyclo-DNA, increases the resistance
to nucleases and tm, allowing for short oligonucleotides
to retain much of their activity in vitro. Furthermore,
several studies have shown that it is possible to improve
the potency of antisense oligonucleotides in vivo by re-
ducing their length to less than 17-mer [27, 33, 34]. The
Fig. 1 Bias of dinucleotide frequencies observed in species of different complexity. Mutational biases CA/AC (a), AT/TA (b), AG/GA (c), GC/CG
(d). Examples of sequences and their frequencies in human cDNA comprising a random collection of low-frequency (e) or high-frequency
dinucleotides are shown (f). Horizontal lines represent ratio 1:1, i.e., no bias. Error bars are contained in data points and represent 95 % confidence
intervals (binomial distributions) in comparison with random expectations. Ec (Escherichia coli CFT073), At (Arabidopsis thaliana), Ce (Caenorhabditis
elegans), Dm (Drosophila melanogaster), Mm (Mus musculus), Hs (Homo sapiens)
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high variance in sequence interactivity of complex or-
ganisms shown in this study facilitates the presence of
targets of this size range common to more than one
mRNA or protein related to a particular trait or disease.
Although the sequences that are shown in Table 1 are in
the format of antisense gapmer oligonucleotides, by aim-
ing at DNA targets, these sequences could alternatively be
used for transcriptional gene silencing or targeted gene
modification with zinc-finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs) or clustered regu-
latory interspaced short palindromic repeat (CRISPR)/Cas-
based methods [35]. Some of these sequences could also be
used in the design of RNA-binding proteins, either alone
[36, 37] or in combination with RNA cleavage domains [38].
Reductions in the size of the targets or the introduction of
abasic sites, e.g., by using spacers, could further increase the
number of genes of interest that are targeted, but it could
also affect the expression of other genes; thus, further ana-
lysis would be necessary.
In regards to peptide sequences, targets present in mul-
tiple proteins and involved in particular human diseases
could be employed as decoys [39, 40], to raise antibodies
[41], delivered directly in the form of stapled peptides [42–
44] or incorporated as loops into naturally occurring cyclic
peptides [45, 46] (Table 2). The structure predicted for these
peptides can be observed in Fig. 4. Finally, sequences present
in multiple homing peptides could specifically recognize
more than one type of tumor [47, 48] (Additional file 3:
Table S3). The accession numbers of all the peptide and
nucleotide sequences that were searched for targets shared
by key pathways can be found in the (Additional files 4:
Table S4) and (Additional file 5: Table S5). Further details
on how the search was performed are in (Additional file 6:
Figure S1).
Discussion
This study describes and encourages the adoption of the
strategy that is used in organisms to modify complex traits
Fig. 2 Increase in the variance of sequence interactivity in the human and mouse genomes. 3D plots of sequence frequency in cDNA relative to
the length and relative interactivity (r. interactivity) measured as the percentage of high-frequency (CA, AT, GC, AG) vs low-frequency dinucleotides
(AC, TA, CG, GA) show an increase in the variance of sequence interactivity in Mus musculus and Homo sapiens (e and f) in comparison with Escherichia
coli (a), Arabidopsis thaliana(b), Caenorhabditis elegans(c) and Drosophyla melanogaster(d)
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to treat diseases with robust pathological phenotypes.
Comparative genomics reveals a striking increase in the
frequency variance of sequences depending on nucleotide
composition in complex organisms. The high variance in
the interactivity of sequences presents an ideal evolution-
ary substrate to recruit sequence-specific regulators that
target multiple gene products. Coding sequences retain
their functionality, while other sequences, mainly the
3’UTR, fluctuate between nucleotide compositions that
are very likely to be complementary to other sequences in
the genome in the search for advantageous interactions.
This feature of the human genome has facilitated the re-
cruitment of an ever increasing sophistication in the sim-
ultaneous regulation of multiple gene products. Recent
advances in biotechnology will allow us to continue form-
ing the next layer of regulation, but this time, the tools will
be assembled in laboratories and stored online.
Sequences as targets of multispecific molecular effectors
The interface between the genetic information contained in
DNA sequences and the environment is shaped by a sophis-
ticated network of regulatory elements. This interface in
complex organisms can be understood from not only the
perspective of positive selection but also other non-
adaptative mechanisms shaping the mutational biases that
tend to form these sequences, rather than natural selection
acting on each sequence individually. The result of this
process is that some sequences are formed more frequently,
regardless of any direct selective pressure.
Natural selection can initially fixate enzymes or miRNAs
with few targets, and then, more targets are added to the pool
by the evolutionary inertness of the sequences, with natural
selection only acting to remove themost deleterious of the in-
teractions. Although outside the scope of this study,maintain-
ing a high variance in the interactivity of its elements and the
interplay of genetic drift and multitarget regulation could be
key to complex organisms outcompeting others by their pace
of innovation. An example of the increase in sequence inter-
activity associated with complexity can be observed in the way
in which miRNAs operate in plants and animals. In plants,
perfect complementarity of miRNAs to their target mRNAs is
required to regulate gene expression. In contrast, in animals,
miRNA complementarity is only necessary for the 5' bases 2
through 7 of the miRNA, and as a result, the same miRNA
can targetmany differentmRNAs [49, 50].
In complexity race scenarios, organisms recruit muta-
tional biases and tend to frequently show mutations toward
states that have previously been favorable for building com-
plexity. The more organized a system is, the more sophisti-
cated are the mechanisms that bias the way in which
tensions are released by mutations or the way in which
these mutations are corrected or expressed to increase
complexity. We are in a unique moment in that soon
(at least from an evolutionary point of view), we will have
the technology to not only ameliorate complex human dis-
eases but also to modify human traits by deliberately modu-
lating the expression of chosen combinations of genes.
Building a library of nucleotide- and peptide-based multi-
specific macromolecules
Modulating gene expression using multitarget regulatory ele-
ments could be the key for ameliorating robust disease
Fig. 3 High variance in the interactivity of sequences facilitates the recruitment of multispecific regulators. (a) Average ratio of dinucleotide
frequencies with the same base composition observed in species of different complexities. (b) Human sequences in the 3’UTR have a very similar
nucleotide composition to the rest of the genome in comparison with the 5’UTR, increasing the likelihood of interactions with other sequences
by complementarity. (c) Relative proportion per nucleotide of the common nucleotide sequences targeting genes of therapeutic interest
identified in this work (considering the average nucleotide size of the 5’UTR, coding sequence and 3’UTR as 200, 1340 and 800 bp, respectively).
Error bars are contained in data points in (A) and (B) and represent 95 % confidence intervals (binomial distributions) in comparison with random
expectations. Horizontal lines represent ratio 1:1, i.e., no bias. Ec (Escherichia coli CFT073), At (Arabidopsis thaliana), Ce (Caenorhabditis elegans), Dm
(Drosophila melanogaster), Mm (Mus musculus), Hs (Homo sapiens)
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phenotypes. The best example in this regard is most likely
cancer, a disease for which the perception is shifting from a
gene-centered, uncontrolled growth scenario to another per-
spective based on highly regulated developmental networks
[51]. However, the situation should be similar for many other
human disorders in which severity has been shown to be de-
termined by more than one gene and/or network. Recently,
combinatory approaches have been actively pursued, e.g., de-
veloping therapies targeting the regulation ofmiRNA levels. A
number of such therapies modulating miRNAs [52] or Hsp90
[53] are being studied in clinical trials.
The main disadvantage of modulating naturally occur-
ring multi-regulatory mechanisms is the off-target effects
that could be potentially caused by targeting mRNAs or
proteins that are unrelated to the targeted pathology. For
example, a particular miRNA can target hundreds of
genes, and while it may be very valuable in developing an
antitumoral therapy, it has not evolved to become the per-
fect switch for a particular kind of cancer. There is room
for improvement by modifying the sequence of miRNAs
or finding other sequences common to mRNAs or pro-
teins of interest.
Table 1 Antisense gapmer oligonucleotides that exclusively
demonstrate reverse complementarity to multiple cDNAs
related to particular disorders. All nucleotides are linked by
phosphorothioate linkages *, and conformationally restricted
nucleotide monomers, such as tricycle-DNA, LNAs and MOEs,
are preceded by +. Additional sequences can be found in Table

































Table 2 Peptide sequences present in multiple proteins
involved in particular human diseases. These peptides could be
used as decoys, antigens to raise antibodies, or if aiming to
intracellular targets delivered directly in the format of stapled
peptides, incorporated as loops into naturally occurring cyclic
peptides, or used after conjugation with molecules that aid in
cellular uptake. Additional sequences can be found in Table S2
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The advantages of tailored multitarget tools could be, first,
to circumvent the regulation of parallel pathways and elem-
ental redundancy in networks. To increase patient coverage
and avoid the appearance of resistance mechanisms in can-
cer treatments, it seems logical to develop therapies that are
able to target multiple gene products or regulators. Second,
using a single sequence would reduce the cost of production
because synthesis, quality control and toxicology would be
limited to one molecule, or a few in the case of using a com-
binatorial approach. An additional advantage of utilizing a
multitarget approach would be to take advantage of any syn-
ergistic effect that could be derived from gene epistasis. Epis-
tasis is often overlooked merely because of the difficulty of
using genetic interactions to estimate heritability accurately
[54, 55]. Lastly, from the point of view of therapeutic effi-
cacy, it is preferable to use short sequences that are common
to several genes of interest to improve their delivery in vivo,
as large sizes can limit biodistribution.
Some of the applications of these designs could be to
carry cancer drugs to tumors, modulate the immune
Fig. 4 Prediction of peptide structures. Further characterization of the peptides included in Table 2, red: helical, green: extended, blue: coil.
Peptide structure was predicted using PEP-FOLD, which is based on hidden Markov models. The structure of these peptides is of importance to
define their usefulness depending on their application (eg to raise antibodies, as decoys etc.)
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system or block the action of a series of gene products.
For example, a possible design could consist of an anti-
body directed to the common peptide sequences present
in the extracellular domain of the fibroblast growth fac-
tor receptors (FGFRs) or their ligands (Table 2 and
Fig. 4). Theses receptors play an important role in cell
proliferation and survival [56] and they are the target of a
number of therapeutic molecules, such as FP-1039, a sol-
uble receptor that acts as a decoy for all the mitogenic
FGF ligands [57]. Furthermore, there is already a growing
interest in using bispecific or multispecific antibodies [58]
whether the targeting is achieved by modularity [59–61]
or even by developing antibodies able to bind to more
than one epitope in a single antigene recognition surface
[62–64]. The peptide structure shown in Fig. 4 was pre-
dicted using PEP-FOLD, which is based on hidden Mar-
kov models [19, 20]. The structure of these peptides is of
importance to define their usefulness depending on their
application (eg to raise antibodies or as decoys) [65]. For
instance, alpha-helical peptides have hydrophobic and
hydrophilic faces that can interact with the membrane to
being internalized.
Ideally, a combination of targets would be available for
each different genetic background leading to the disease,
and the corresponding cocktail of macromolecules would
be validated as being able to ameliorate the pathology. In
reality, generating an ideal set of guidelines for the gene
therapy of complex diseases is not a simple task of linking
mutant genotypes with the tools that are able to modify
the expression of a number of genes. Despite recent
advances, predicting phenotypes from genotypes is not
straightforward [66]. Additionally, only some of the com-
mon sequences would be amenable for the design of
therapeutic tools. Therefore, a future set of guidelines for
the use of these macromolecules will presumably require
multiple rounds of bioinformatic analysis and empirical
validation. In this context, a database such as wikisequen-
ces.org containing these and other sequences and open to
comments and performance reports across different stud-
ies could be valuable to facilitate empirical validation.
Conclusions
Most human traits and diseases are caused by multiple en-
vironmental and genetic causes, with each one of them
having a relatively small effect. In contrast, most macro-
molecular therapies focus on targeting a single receptor or
modulating the abundance of a single gene product. This
work defines and promotes the adoption of the same mul-
titarget strategy that has evolved in organisms to modify
complex traits in order to simultaneously target key path-
ways of human disorders with robust phenotypes, such as
cancer and immune disorders.
The genomic sequences of mouse and human show an
increase in the frequency variance of sequences depending
on the nucleotide composition in comparison with organ-
isms of lower complexity. The mutational biases inferred
from the genomic sequences can lead to a high variance
in the interactivity of the sequences, facilitating the re-
cruitment of sequence-specific regulators that are able to
target multiple gene products. For example, sequences in
the 3’UTR seem to be more free of constraints in com-
parison with the 5’UTR to mutate towards a very similar
nucleotide composition to the rest of the genome, increas-
ing the likelihood of interacting with other sequences in
the genome due to complementarity.
Taking into account the importance of multitargeting
for modifying robust phenotypes, a script to search for
sequences with the potential for multitarget regulation
and genes of interest in the medical literature was uti-
lized to build a library of nucleotide- and peptide-based
tools to target more than one gene product involved in a
particular human disease that is not included in any
other mRNA or protein. This resource is open to other
users at www.wikisequences.org to upload other designs
of interest, comment on their performance and link
them to other manuscripts.
Among the main advantages of tailored multitarget
macromolecules is the limitation of the off-target effects
caused by modulating natural multi-regulatory elements
such as miRNAs and Hsp90. Second, multitargeting cir-
cumvents the regulation of parallel pathways and develop-
ing redundancy in cancer networks. Third, multitargeting
would reduce the cost of production because a smaller
number of different molecules would be needed to target
the same number of gene products or receptors. Fourth,
combinatorial approaches can take advantage of any syn-
ergistic effect that could be derived from gene epistasis. Fi-
nally, from the point of view of delivery, it is preferable to
use short sequences that are common to several genes of
interest rather than compound designs that would hamper
in vivo efficacy. This last point of delivery is always cited
as the limiting factor for many avant-garde therapies
based on macromolecules, but advances not only in deliv-
ery but also in multitargeting could be also important for
macromolecules to overcome the current advantages of
small molecules in the clinic.
Additional files
Additional file 1: Table S1. Antisense gapmer oligonucleotides that
exclusively demonstrate reverse complementarity to multiple cDNAs
related to particular disorders.
Additional file 2: Table S2. Peptide sequences present in multiple
proteins involved in particular human diseases.
Additional file 3: Table S3. Peptide sequences present in multiple
homing peptides that specifically recognize cancer cells or tumor vessels.
Additional file 4: Table S4. Accession numbers of nucleic acid
sequences that were searched for targets shared by key pathways cancer
Varela BMC Genomics  (2015) 16:530 Page 9 of 11
and immune diseases to facilitate the design of new multispecific
methods to treat complex diseases.
Additional file 5: Table S5. Accession numbers of peptides that were
searched for targets shared by key pathways cancer and immune
diseases to facilitate the design of new multispecific methods to treat
complex diseases.
Additional file 6: Figure S1. Identification of sequences shared by
multiple genes to form a library of nucleotide- and peptide-based tools
capable of simultaneously targeting key pathways.
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